|
業務類別
|
-- |
|
業務概覽
|
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Itsproduct candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602. |
| 公司地址
| No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN |
| 電話號碼
| +86 2161493800 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ocumension.com |
| 員工數量
| 489 |
| Dr. Zhaopeng Hu, PhD |
Director and Chief Development Officer |
-- |
28/04/2025 |
| Mr. Ye Liu |
Chief Executive Officer and Director |
-- |
28/04/2025 |
|
|
| Dr. Lian Yong Chen, PhD |
Non-Executive Chairman of the Board |
28/04/2025 |
| Mr. Ting Yuk Anthony Wu |
Independent Director |
28/04/2025 |
| Mr. Yiran Huang |
Independent Director |
28/04/2025 |
| Dr. Zhaopeng Hu, PhD |
Director and Chief Development Officer |
28/04/2025 |
| Mr. Zhenyu Zhang |
Independent Director |
28/04/2025 |
| Dr. Qin Xie |
Director |
28/04/2025 |
| Mr. Ye Liu |
Chief Executive Officer and Director |
28/04/2025 |
| Mr. Yanling Cao |
Director |
28/04/2025 |
|
|
|
|
